Highlight
Once-weekly somapacitan is a novel growth hormone (GH) replacement therapy approved for adults with GH deficiency, showing similar efficacy to daily somatropin on lean mass. Although somapacitan is linked to increased adiposity indices, it improves HDL cholesterol and physical performance measures such as handgrip strength and mobility. This real-world, prospective study demonstrates functional benefits despite differing metabolic trajectories, underscoring the importance of personalized therapy selection.
